Lucid Diagnostics Inc. (LUCD) Stock

About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. is led by CEO Lishan Aklog, employs 72 people, headquartered in US, publicly traded since 2021.

Lucid Diagnostics Inc. (LUCD) stock trades at $0.41 with a market capitalization of $78.48M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.35, reflecting a net loss over the last twelve months, price-to-book of 10.51, price-to-sales of 21.98. Over the past 52 weeks the stock has ranged between $0.31 and $1.63, and currently trades 74.8% below its 52-week high.

On profitability, Lucid Diagnostics Inc. generates a return on equity (ROE) of -404.34% (negative, reflecting a net loss), return on capital employed of -443.44%, an operating margin of -1000.00%, a net profit margin of -959.76%.

Lucid Diagnostics Inc. by the numbers, 2018–2025

Between 2018 and 2025 Lucid Diagnostics Inc. reported revenue of $0 rising to $5.0M. Compounded, revenue has grown —% a year over five years, —% over three, 25.0% over the last twelve months. Net profit fell to $-58.0M.

The most recent net margin is -959.76%. On a trailing twelve-month basis to Jun '26, revenue is $5.0M and net profit $-52.0M.

Borrowings stand at $26.0M, cash from operations was $-46.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged 181.7% over five years, and was -527.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Lucid Diagnostics Inc. (LUCD) — frequently asked questions